ImmunoGen, Inc. (NASDAQ:IMGN) was the target of some unusual options trading activity on Tuesday. Stock traders acquired 634 put options on the company. This represents an increase of 1,119% compared to the average volume of 52 put options.
Shares of ImmunoGen (NASDAQ IMGN) opened at $8.01 on Friday. The company has a market cap of $1,240.00, a P/E ratio of -6.16 and a beta of 2.20. The company has a debt-to-equity ratio of -0.03, a current ratio of 2.81 and a quick ratio of 2.78. ImmunoGen has a 12 month low of $2.20 and a 12 month high of $8.84.
ImmunoGen (NASDAQ:IMGN) last released its earnings results on Friday, November 3rd. The biotechnology company reported ($0.61) EPS for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.42). The company had revenue of $8.50 million for the quarter, compared to the consensus estimate of $26.09 million. The firm’s quarterly revenue was up 10.4% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.51) EPS. analysts anticipate that ImmunoGen will post -0.97 earnings per share for the current fiscal year.
A number of analysts have recently weighed in on the stock. BidaskClub upgraded shares of ImmunoGen from a “hold” rating to a “buy” rating in a report on Thursday. Jefferies Group restated a “buy” rating and issued a $9.00 price target on shares of ImmunoGen in a report on Thursday, October 12th. Cantor Fitzgerald restated a “hold” rating and issued a $5.00 price target on shares of ImmunoGen in a report on Monday, September 25th. ValuEngine cut shares of ImmunoGen from a “hold” rating to a “sell” rating in a report on Thursday, September 21st. Finally, Zacks Investment Research upgraded shares of ImmunoGen from a “hold” rating to a “buy” rating and set a $6.50 target price for the company in a research note on Tuesday, October 31st. Two equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and seven have assigned a buy rating to the stock. ImmunoGen currently has an average rating of “Hold” and a consensus target price of $7.83.
A number of hedge funds have recently added to or reduced their stakes in the stock. Schwab Charles Investment Management Inc. boosted its stake in ImmunoGen by 18.5% in the 4th quarter. Schwab Charles Investment Management Inc. now owns 522,964 shares of the biotechnology company’s stock worth $3,353,000 after purchasing an additional 81,519 shares in the last quarter. Cubist Systematic Strategies LLC acquired a new stake in ImmunoGen during the 3rd quarter valued at approximately $143,000. Perceptive Advisors LLC acquired a new stake in ImmunoGen during the 3rd quarter valued at approximately $536,000. Allianz Asset Management GmbH acquired a new stake in ImmunoGen during the 3rd quarter valued at approximately $1,780,000. Finally, Trexquant Investment LP lifted its stake in ImmunoGen by 220.0% during the 3rd quarter. Trexquant Investment LP now owns 104,633 shares of the biotechnology company’s stock valued at $800,000 after acquiring an additional 71,936 shares during the period. Institutional investors own 68.02% of the company’s stock.
WARNING: This article was reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this article on another domain, it was illegally stolen and republished in violation of United States and international trademark and copyright laws. The original version of this article can be accessed at https://www.dispatchtribunal.com/2018/01/19/stock-traders-buy-large-volume-of-put-options-on-immunogen-imgn.html.
ImmunoGen Company Profile
ImmunoGen, Inc is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its antibody-drug conjugate (ADC) technology. An ADC with the Company’s technology comprises an antibody that binds to a target found on tumor cells conjugated to one of its anti-cancer agents as a payload to kill the tumor cell once the ADC has bound to its target.
Receive News & Ratings for ImmunoGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmunoGen and related companies with MarketBeat.com's FREE daily email newsletter.